Capital Health has signed up to participate in the 3D-PREDICT clinical trial sponsored by KIYATEC, Inc. to validate the company’s test as a patient-specific predictor of response to cancer therapies in glioblastoma (GBM) and anaplastic astrocytoma (AA) patients. Presently Capital Health is the only healthcare system in New Jersey, Pennsylvania and the New York City region enrolling GBM patients in the study.
What is the 3D-PREDICT Study?
The study is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient’s biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers. Involving a target of 570 patients, the study will conclude on June 2022.
Who is Capital Health?
Capital Health is a regional leader in providing progressive, quality patient care with significant investments in their exceptional physicians, nurses, and staff, as well as advanced technology. Comprised of two hospitals (Regional Medical Center in Trenton and Capital Health Medical Center in Hopwell), their Hamilton outpatient facility and various primary and specialty care practices across the region.
Who is KIYATEC?
KIYATEC leverages its proprietary ex vivo 3D cell culture technology platform to accurately model and predicts response to approved and investigational cancer drugs targeting a spectrum of solid tumors. Their clinical services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma, and rare tumors, in its CLIA-certified laboratory.
Their drug development services group works in partnership with leading biopharma companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.
Founded in 2005, the firm has raised approximately $3.2 million according to CrunchBase. The firm employs approximately 20 to 30 employees.Source: Yahoo! Finance